Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dieckol is a **phlorotannin**, a type of marine polyphenol compound isolated mainly from brown algae including *Ecklonia cava*, *Ecklonia stolonifera*, and *Eisenia bicyclis*. It exhibits a range of bioactivities, including **antioxidant**, **anticoagulant**, **hepatoprotective**, **antimicrobial**, **anticancer**, **antiaging**, **antidiabetic**, **neuroprotective**, and anti-inflammatory properties[1][5][8][9]. Mechanistically, dieckol acts as a **positive allosteric modulator** at the benzodiazepine (BZD) binding site of **GABA-A receptor**, enhancing non-REM sleep in preclinical models[3]. It is also reported to inhibit **alpha-glucosidase**, **PI3K/AKT signaling** (relevant in cancer cell proliferation), and **platelet aggregation/thrombosis**[1][3][9]. Dieckol is under investigation for a variety of potential uses including in the food, pharmaceutical, and cosmetic industries, but is not an approved pharmaceutical drug[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dieckol.